Plasma apelin levels, blood pressure and cardiovascular risk factors in a coastal Chinese population

Annals of Medicine

Volumn 45, Issue 7, 2013, Pages 494-498

  Zhu, Pengli ^a   Feng, Huang ^a   Lin, Fan ^a   Yuan, Yin ^a   Chen, Falin ^a   Li, Qiaowei ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Apelin; Blood pressure; Cardiovascular risk; Epidemiology

Indexed keywords

ALBUMIN; APELIN; C REACTIVE PROTEIN; MICROALBUMIN; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR RISK; CHINESE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; SEASHORE; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTERIAL PRESSURE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHINA; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS;

EID: 84885662330     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2013.833767     Document Type: Article

References (23)

1. Charles CJ. Putative role for apelin in pressure/volume homeostasis and cardiovascular disease. Cardiovsc Hematol Agents Med Chem. 2007; 5 : 1-10.
2. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998; 251: 471-6.
3. Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem. 2000; 74 : 34-41.
4. Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept. 2004; 118 : 119-25.
5. Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y, Hinuma S, et al. Molecular and function characteristic of APJ: tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem. 2000; 275 : 21061-7.
6. Cheng X, Cheng XS, Pang CC. Venous dilator eff ect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol. 2003; 470: 171-5.
7. Lee DK, Saldivia VR, Nguyen T, Cheng R, George SR, O'Dowd BF. Modifi cation of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology. 2005; 146: 231-6.
8. Salcedo A, Garijo J, Monge L, Fern á ndez N, Luis García-Villalón A, Sánchez Turrión V, et al. Apelin eff ects in human splanchnic arteries. Role of nitric and prostanoids. Regul Pept. 2007; 144: 50-5.
9. Japp AG, Gruden NL, Amer DA, Li VK, Goudie EB, Johnston NR, et al. Vascular eff ects of apelin in vivo in man. J Am Coll Cardiol. 2008; 52 : 908-13.
10. Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, et al. The novel peptide apelin lowers blood pressure via a nitric oxidedependent mechanism. Regul Pept. 2001; 99: 87-92.
11. Ishida J, Hashimoto T, Hashimoto Y, Nishiwaki S, Iguchi T, Harada S, et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem. 2004; 279 : 26274-9.
12. Barnes GD, Alam S, Carter G, Pedersen CM, Lee KM, Hubbard TJ, et al. Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure. Circ Heart Fail. 2013; 6 : 482-91.
13. A merican Diabetes Association. S tandards of medical care in diabetes- 2011. Diabetes Care. 2011; 34: S11-61.
14. Jia YX, Lu ZF, Zhang J, Pan CS, Yang JH, Zhao J, et al. Apelin activates L-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides. 2007; 28: 2023-9.
15. Zhong JC, Huang DY, Liu GF, Jin HY, Yang YM, Li YF, et al. Effects of all-trans retinoic acid on orphan receptor APJ signaling in spontaneously hypertensive rats. Cardiovasc Res. 2005; 65: 743-50.
16. Zhong JC, Huang DY, Yang YM, Li YF, Liu GF, Song XH, et al. Upregulation of angiotension-converting enzyme 2 by all-trans retinoic acid in spontaneously hypertensive rats. Hypertension. 2004; 44: 907-12.
17. Sonmez A, Celebi G, Erdem G, Tapan S, Genc H, Tasci I, et al. Plasma apelin and ADMA levels in patients with essential hypertension. Clin Exp Hypertens. 2010; 32: 179-83.
18. Strazynska A, Bryl W, Hoff mann K, P upek-Musialik D. The estimation of concentration of apelin, insulin, fasting glucose and anthropometric factors in young hypertensive patients. J Hypertens. 2010; 28 (e-Supplement A): e187.
19. Li WW, Niu WQ, Zhang Y, Wu S, Gao PJ, Zhu DL. Family-based analysis of apelin and AGTRL1 gene polymorphisms with hypertension in Han Chinese. J Hypertens. 2009; 27: 1194-201.
20. Niu W, Wu S, Zhang Y, Li W, Ji K, Gao P, et al. Validation of genetic association in apelin-AGTRL1 system with hypertension in a larger Han Chinese population. J Hypertens. 2010; 28: 1854-61.
21. Wang W, Lee ET, Fabsitz RR, Devereux R, Best L, Welty TK, et al. A longitudinal study of hypertension risk factors and their relation to cardiovascular disease: the Strong Heart Study. Hypertension. 2006; 47: 403-9.
22. Sung KC, Suh JY, Kim BS, Kang JH, Kim H, Lee MH, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens. 2003; 16: 429-33.
23. Andrievskaia EM, Ivleva AIa, Minina ES, Lagutina OE. [Predictive value C-reactive protein assessment level in women with arterial hypertension]. Kardiologiia. 2011; 51: 32-8.